During the past decade, Texas Institute of Cardiology conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 1 clinical trials were completed, i.e. on average, 11.1% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 1 clinical trials were completed. i.e. 14.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Institute of Cardiology" #1 sponsor was "Amgen" with 3 trials, followed by "Eli Lilly and Company" with 2 trials sponsored, "Zoll Medical Corporation" with 2 trials sponsored, "GE Healthcare" with 1 trials sponsored and "Ionis Pharmaceuticals, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Institute of Cardiology" #1 collaborator was "ABX CRO" with 1 trials as a collaborator, "AG Mednet Inc." with 1 trials as a collaborator, "Advanced Clinical, LLC" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator and "H2O Clinical LLC" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Texas Institute of Cardiology" are "Heart Failure" (4 trials), "ASCVD" (1 trials), "Atherosclerotic Cardiovascular Disease" (1 trials), "Coronary Heart Disease (CHD)" (1 trials) and "Heart Failure With Preserved Ejection Fraction" (1 trials). Many other conditions were trialed in "Texas Institute of Cardiology" in a lesser frequency.

Most popular intervention types in "Texas Institute of Cardiology" are "Drug" (5 trials), "Device" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Evolocumab" (1 trials), "Implantable Cardioverter Defibrillator" (1 trials), "Iobenguane I -123 Injection" (1 trials) and "LY3540378" (1 trials). Other intervention names were less common.

The vast majority of trials in "Texas Institute of Cardiology" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Texas Institute of Cardiology". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Texas Institute of Cardiology, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Institute of Cardiology, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".